The esophageal distension-gastric relaxation response or "receptive relaxation reflex" [RRR] is an autonomic mechanism which normally increases gastric volume and reduces intragastric pressure to assure that swallowed food is efficiently transported to and retained by the stomach. There is a large body of descriptive literature which supports the existence of the RRR in a number of species including rats and humans. This reflex is mediated largely, is not exclusively by a vagal afferent-CNS-vagal efferent pathway. Failure of this reflex mechanism has been held responsible for a number of serious swallowing and reflux disorders. This circuitry, which produces gastric relaxation, may also play a critical role in the perception of nausea and the production of emesis. Our preliminary results suggest that the central RR circuitry of esophageal vagal afferent connections with the nucleus of the solitary tract, pars centralis (NSTc] which, in turn, projects throughout the entire dorsal motor nucleus of the vagus [DMN]. DMN efferents which control the motility and compliance functions of the stomach are separable into two distinct vagal pathway. The other DMN projection to the stomach probably activates a non-adrenergic non-cholinergic [NANC] enteric circuit. Based on our preliminary physiological data we formulate the following hypotheses: the NSTc neurons activated by esophageal afferent input operate on these two separate DMN pathways to the stomach such that the muscarinic ["excitatory"] pathway is inhibited while the NANC ["inhibitory"] pathway is activated. The combination of effects produces a profound relaxation. Furthermore, we predict that a previously identified corticotrophin releasing hormone [CRH]- ergic CNS mechanism activated by psychological stress produces gastric stasis by activating RR circuit elements in the dorsal vagal complex. These predictions will be tested by a combination of in vivo and in vitro neurophysiological and immunocytochemical protocols.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
848
DUNS Number
832127323
UEI
DLWBSLWAJWR1
Project Start Date
01-September-1999
Project End Date
31-December-2001
Budget Start Date
01-September-2001
Budget End Date
31-December-2001
Project Funding Information for 2001
Total Funding
$44,646
Direct Costs
$41,656
Indirect Costs
$2,990
Year
Funding IC
FY Total Cost by IC
2001
National Institute of Diabetes and Digestive and Kidney Diseases
$44,646
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DK056373-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DK056373-03
Patents
No Patents information available for 5R01DK056373-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DK056373-03
Clinical Studies
No Clinical Studies information available for 5R01DK056373-03
News and More
Related News Releases
No news release information available for 5R01DK056373-03
History
No Historical information available for 5R01DK056373-03
Similar Projects
No Similar Projects information available for 5R01DK056373-03